These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 33362770)
1. Targeting IL-1β in the Treatment of Atherosclerosis. Mai W; Liao Y Front Immunol; 2020; 11():589654. PubMed ID: 33362770 [TBL] [Abstract][Full Text] [Related]
2. A perspective on targeting inflammation and cytokine actions in atherosclerosis. Chan YH; Ramji DP Future Med Chem; 2020 Apr; 12(7):613-626. PubMed ID: 32175772 [TBL] [Abstract][Full Text] [Related]
3. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610 [TBL] [Abstract][Full Text] [Related]
4. Atherosclerosis: perspectives of anti-inflammatory therapy. Nasonov EL; Popkova TV Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884 [TBL] [Abstract][Full Text] [Related]
5. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Ridker PM Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995 [TBL] [Abstract][Full Text] [Related]
6. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis. Khan R; Rheaume E; Tardif JC Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131 [TBL] [Abstract][Full Text] [Related]
13. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Grebe A; Hoss F; Latz E Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500 [TBL] [Abstract][Full Text] [Related]
14. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629 [TBL] [Abstract][Full Text] [Related]
20. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]